Pacira BioSciences, Inc.

NasdaqGS:PCRX Stock Report

Market Cap: US$772.5m

Pacira BioSciences Valuation

Is PCRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PCRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PCRX ($17.03) is trading below our estimate of fair value ($78.65)

Significantly Below Fair Value: PCRX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PCRX?

Key metric: As PCRX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PCRX. This is calculated by dividing PCRX's market cap by their current revenue.
What is PCRX's PS Ratio?
PS Ratio1.1x
SalesUS$694.96m
Market CapUS$772.48m

Price to Sales Ratio vs Peers

How does PCRX's PS Ratio compare to its peers?

The above table shows the PS ratio for PCRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average22.3x
EYPT EyePoint Pharmaceuticals
13.7x44.8%US$646.2m
LQDA Liquidia
54.9x59.6%US$859.9m
PAHC Phibro Animal Health
0.9x2.7%US$962.0m
ZVRA Zevra Therapeutics
19.6x50.3%US$478.8m
PCRX Pacira BioSciences
1.1x0.6%US$772.5m

Price-To-Sales vs Peers: PCRX is good value based on its Price-To-Sales Ratio (1.1x) compared to the peer average (22.3x).

Price to Sales Ratio vs Industry

How does PCRX's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

73 CompaniesPrice / SalesEstimated GrowthMarket Cap
OGN Organon
0.6x-0.06%US$3.76b
PRGO Perrigo
0.8x3.4%US$3.72b
BHC Bausch Health Companies
0.3x1.5%US$3.01b
AMRX Amneal Pharmaceuticals
1x5.6%US$2.62b
PCRX 1.1xIndustry Avg. 2.5xNo. of Companies73PS048121620+
73 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: PCRX is good value based on its Price-To-Sales Ratio (1.1x) compared to the US Pharmaceuticals industry average (2.5x).

Price to Sales Ratio vs Fair Ratio

What is PCRX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PCRX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.1x
Fair PS Ratio2.3x

Price-To-Sales vs Fair Ratio: PCRX is good value based on its Price-To-Sales Ratio (1.1x) compared to the estimated Fair Price-To-Sales Ratio (2.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PCRX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$17.03
US$18.00
+5.7%
50.7%US$39.00US$8.00n/a8
Nov ’25US$16.57
US$18.50
+11.6%
51.5%US$39.00US$8.00n/a8
Oct ’25US$15.30
US$18.38
+20.1%
52.1%US$39.00US$8.00n/a8
Sep ’25US$15.56
US$18.00
+15.7%
53.6%US$39.00US$8.00n/a8
Aug ’25US$20.75
US$38.44
+85.3%
23.7%US$57.00US$25.00n/a9
Jul ’25US$28.46
US$44.90
+57.8%
14.9%US$57.00US$36.00n/a10
Jun ’25US$30.33
US$44.90
+48.0%
14.9%US$57.00US$36.00n/a10
May ’25US$26.95
US$45.30
+68.1%
14.3%US$57.00US$36.00n/a10
Apr ’25US$29.15
US$45.30
+55.4%
14.3%US$57.00US$36.00n/a10
Mar ’25US$28.86
US$45.56
+57.9%
14.3%US$57.00US$38.00n/a9
Feb ’25US$31.78
US$47.67
+50.0%
13.6%US$57.00US$38.00n/a9
Jan ’25US$33.74
US$48.40
+43.4%
14.0%US$58.00US$38.00n/a10
Dec ’24US$27.81
US$49.11
+76.6%
13.8%US$58.00US$38.00n/a9
Nov ’24US$28.31
US$54.67
+93.1%
11.9%US$67.00US$46.00US$16.579
Oct ’24US$30.68
US$55.67
+81.4%
11.9%US$68.00US$46.00US$15.309
Sep ’24US$35.53
US$55.67
+56.7%
11.9%US$68.00US$46.00US$15.569
Aug ’24US$36.00
US$61.78
+71.6%
15.1%US$80.00US$48.00US$20.759
Jul ’24US$40.07
US$63.00
+57.2%
14.2%US$80.00US$50.00US$28.469
Jun ’24US$38.04
US$64.70
+70.1%
15.3%US$80.00US$50.00US$30.3310
May ’24US$46.60
US$65.20
+39.9%
15.5%US$80.00US$50.00US$26.9510
Apr ’24US$40.81
US$65.80
+61.2%
16.2%US$80.00US$50.00US$29.1510
Mar ’24US$43.38
US$65.45
+50.9%
19.0%US$90.00US$50.00US$28.8611
Feb ’24US$40.57
US$67.00
+65.1%
18.6%US$90.00US$50.00US$31.7811
Jan ’24US$38.61
US$72.45
+87.7%
15.7%US$90.00US$50.00US$33.7411
Dec ’23US$47.23
US$73.55
+55.7%
14.3%US$90.00US$54.00US$27.8111
Nov ’23US$52.45
US$76.70
+46.2%
14.9%US$94.00US$54.00US$28.3110

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

IQVIA Holdings

US$34.7b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$194.38

7D

-8.1%

1Y

-7.2%

Collegium Pharmaceutical

US$959.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.00

7D

-0.6%

1Y

15.5%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.10

7D

-7.9%

1Y

6.6%